<DOC>
	<DOCNO>NCT02751424</DOCNO>
	<brief_summary>A phase I , first-time-in-human ( FTIH ) , randomize , double-blind , placebo control , dose-escalation study conduct determine safety , tolerability , pharmacokinetic ( PK ) profile GSK3342830 administration single intravenous ( IV ) infusion Part 1 repeat IV infusion Part 2 healthy subject . Part 1 investigate escalate single IV dose GSK3342830 . Part 2 , investigate escalate repeat IV dose GSK3342830 repeat dose 15 day follow : single IV infusion Day 1 , TID ( three time day ) IV infusion Days 2 14 ( approximately every 8 hour ) , single IV infusion Day 15 . The planned start GSK3342830 dose Part 1 250 milligram ( mg ) administer single IV infusion . The dose planned increase subsequent cohorts 500 , 1000 , 2000 , 4000 , less equal ( ≤ ) 6000 mg. Part 1 divide 6 cohort ( A-F ) cohort enroll 10 subject ( 6 active 2 placebo ) . Dose escalation conduct supported preliminary safety , tolerability , PK result precede dose level study . The repeat dose escalation component ( Part 2 ) study plan initiate completion evaluation single dose cohort include 4000 mg .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Pharmacokinetics Ascending Intravenous Single Dose Repeat Dose GSK3342830</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Between 18 55 year age , inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include investigator feel document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; 50 kilogram ( kg ) ( 110 pound [ lb ] ) men &gt; 40 kg ( 99 lb ) woman body mass index within range 18.5 30 kg per square meter ( m^2 ) , inclusive . Male Female subject . Males : Male subject female partner childbearing potential must agree use one highly effective contraception time first dose study drug completion Followup visit , Females : A female subject eligible participate pregnant ( confirm negative serum human chorionic gonadotropin [ hCG ] test ) , lactate , consider nonreproductive potential ( nonreproductive potential define : Premenopausal females one following : Documented tubal ligation Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion Hysterectomy Documented bilateral oophorectomy ) . Postmenopausal define 12 month spontaneous amenorrhea questionable case blood sample simultaneous folliclestimulating hormone ( FSH ) estradiol level consistent menopause ( refer laboratory reference range confirmatory level ) Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method , wish continue HRT study . Otherwise , must discontinue HRT allow confirmation post menopausal status study enrolment . Capable give sign informed consent , include compliance requirement restriction . Alanine aminotransferase ( ALT ) within normal limit ; bilirubin &gt; 1.5× upper limit normal ( ULN ; isolate bilirubin &gt; 1.5× ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Corrected QT ( QTc ) &gt; 450 millisecond ( msec ) . Any clinically significant central nervous system ( e.g. , seizure ) , cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal condition history condition , opinion investigator , may place subject unacceptable risk participant trial may interfere absorption , distribution , metabolism , excretion drug . Use systemic antibiotic within 30 day screen . Ongoing febrile illness . Confirmed history Clostridium difficile diarrhea Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) first dose study treatment , unless opinion Investigator , medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month screen defined average weekly intake &gt; 21 unit ( average daily intake &gt; 3 unit ) male average weekly intake &gt; 14 unit ( average daily intake &gt; 2 unit ) female . One unit equivalent 270 milliliter ( mL ) full strength beer , 470 mL light beer , 30 mL spirit , 100 mL wine . Urinary cotinine level indicative smoking history regular use tobacco nicotine containing product within 3 month screen . History hypersensitivity attribute betalactam antibiotic ( include cephalosporin , carbapenem , penicillin antibiotic ) drug , history multiple antibiotic intolerance , history serious adverse drug reaction . Sensitivity poison ivy catecholrelated hypersensitivity ( e.g. , mango allergy ) . History sensitivity heparin heparininduced thrombocytopenia . History latex allergy . History sensitivity study treatment component thereof , history drug allergy , opinion investigator , contraindicate participation study . Presence hepatitis B surface antigen positive hepatitis C antibody test result screen within 3 month first dose day study . Serum creatinine &gt; ULN . Glomerular filtration rate &lt; 90 millilter per minute per 1.73 square meter ( mL/min/1.73m^2 ) calculate Chronic Kidney Disease Epidemiology Collaboration formula Albumin creatinine ratio ( ACR ) &gt; 0.03 mg/mg . In event ACR threshold , eligibility may confirm second measurement . Urinalysis positive blood without cause identify . A positive prestudy drug alcohol screen . A positive test human immunodeficiency virus antibody screen . Participation study would result donation blood blood product excess 500 mL within 56day period . The subject participate clinical trial receive investigational product within following time period first dose day study : 30 day , 5 half life twice duration biological effect investigational product ( whichever longer ) . Exposure 4 new chemical entity within 12 month first dose day study . Exclusion criterion screen baseline 12lead ECG : Heart rate &lt; 40 &gt; 100 beat per minute male &lt; 50 &gt; 100 beat per minute ( female ) , pulse rate &lt; 120 &gt; 220 msec , QRS &lt; 70 &gt; 120 msec , correct QT interval use Bazett 's formula ( QTcB ) correct QT interval use Fridericia 's formula ( QTcF ) &gt; 450 msec.. Also apart , subject evidence previous myocardial infarction , bundle branch block Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high ] , WolfParkinsonWhite syndrome ) , sinus pause 3 second , nonsustained sustain ventricular tachycardia ( &gt; =3 consecutive ventricular ectopic beat ) , significant arrhythmia , opinion investigator interfere safety individual subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multidrug-resistant</keyword>
	<keyword>Gram negative bacterial infection</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>